| Objective Analyze treatment outcome of Omalizumab in chronic urticaria,prurigo nodosa,atopic dermatitis and other diseases,observe treatment of Omalizumab in pruritus,explore the best indications of Omalizumab,and standardize the use of drugs.At the same time monitor adverse reaction during treatment.Methods Collect and analyze patients with chronic urticaria,prurigo nodosa,and atopic dermatitis who were treated at Hainan Boao Super Hospital and Hefei Fei Rui Dermatological Research Center from December 2018 to January 2021.Formulate the diagnosis and treatment plan for each patient,including the dosage and time of administration before the follow-u The follow-up period is 12 weeks,and every 4 weeks is a follow-up period.Collect the general condition of the patient,evaluate the scale data,and complete the follow-up period.Summarize general data and scale data during the follow-up period,general data summarize patient characteristics,and scale data to evaluate disease changes.SPSS software analyzes the difference between the changes before and after the scale(week 0 and week 4,week 0 and week 8,week 0 and week 12)to explain the relationship between disease changes and the scale,so as to get treatment curative effect before and after.Pearson correlation analysis was performed in the selected scales,and the plan of improving the disease scale evaluation was selected while evaluating the patient’s condition.Result Omalizumab can reduce the urticaria quality of life score(CU-Q2 o L)and the dermatology life quality index(DLQI),improve the quality of life of patients,and reduce the urticaria activity score(UAS)and the 7-day urticaria activity score(UAS7),reduce disease activity,improve the urticaria control test(UCT),and control the disease at a good level in the treatment of urticaria.In terms of scale correlation: urticaria quality of life score(CU-Q2 o L)and dermatology life quality index(DLQI)was highly positively correlated,and the 7-day urticaria activity score(UAS7)and the urticaria control test(UCT)were highly negatively correlated.Omalizumab treatment of atopic dermatitis in the follow-up of dermatology life quality index(DIQL)and pruritus numerical score(NRS)were reduced,but the reduction of eczema area and severity index(EASI)was low,the patient’s quality of life has been improved,but the reduction of skin lesions is not effective.Omalizumab has also been shown to improve the quality of life of patients and reduce itching in the treatment of prurigo nodosa.The dermatological quality of life score(DIQL)and the number rating scale(NRS)have been reduced,but they are not effective.The evaluation data and sample size are small.In terms of scale correlation,the dermatology life quality index(DIQL)and the number rating scale(NRS)are highly positively correlated.Conclusion In China,the application of omalizumab in the treatment of chronic urticaria is safe and effective,and its efficacy is less affected by different treatment options.According to the relevance of the scale,the most suitable scale for patients can be selected and the quality of life for dermatology life quality index(DIQL),7-day urticaria activity score(UAS7)and urticaria control test(UCT)to simplify the follow-up process.Omalizumab can improve the quality of life of patients in atopic dermatitis,but the effect of reducing and removing skin lesions is not good.At the same time,Omalizumab can achieve a goal of reducing itching in patients with prurigo nodularis.However,there is no unified standard for disease assessment.It cannot be said that omalizumab is effective in the treatment of prurigo nodularis.The treatment plan for prurigo needs further improvement.Although the dermatological quality of life score(DIQL)and the number rating scale(NRS)are highly correlated,the two reflect different disease conditions and can be selected at the right time according to the condition.In addition,the scale suitable for the specific disease can be selected in the specific disease. |
PDF Full Text Request